Last reviewed · How we verify
MK-1167
At a glance
| Generic name | MK-1167 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (PHASE1)
- A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) (PHASE2)
- A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (PHASE1)
- Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) (PHASE1)
- A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006) (PHASE1)
- A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-1167 CI brief — competitive landscape report
- MK-1167 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI